161 related articles for article (PubMed ID: 31475974)
1. A Human Peripheral Blood Mononuclear Cell (PBMC) Engrafted Humanized Xenograft Model for Translational Immuno-oncology (I-O) Research.
Li Z; Yang X; Zhang Y; Yang X; Cui X; Zhang Y; Gong W; Bai H; Liu N; Tang Z; Guo M; Li K; Zhang T; Wang L; Song X
J Vis Exp; 2019 Aug; (150):. PubMed ID: 31475974
[TBL] [Abstract][Full Text] [Related]
2. Promising preclinical platform for evaluation of immuno-oncology drugs using Hu-PBL-NSG lung cancer models.
Pyo KH; Kim JH; Lee JM; Kim SE; Cho JS; Lim SM; Cho BC
Lung Cancer; 2019 Jan; 127():112-121. PubMed ID: 30642538
[TBL] [Abstract][Full Text] [Related]
3. Establishment of peripheral blood mononuclear cell-derived humanized lung cancer mouse models for studying efficacy of PD-L1/PD-1 targeted immunotherapy.
Lin S; Huang G; Cheng L; Li Z; Xiao Y; Deng Q; Jiang Y; Li B; Lin S; Wang S; Wu Q; Yao H; Cao S; Li Y; Liu P; Wei W; Pei D; Yao Y; Wen Z; Zhang X; Wu Y; Zhang Z; Cui S; Sun X; Qian X; Li P
MAbs; 2018; 10(8):1301-1311. PubMed ID: 30204048
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models.
Rosato RR; Dávila-González D; Choi DS; Qian W; Chen W; Kozielski AJ; Wong H; Dave B; Chang JC
Breast Cancer Res; 2018 Sep; 20(1):108. PubMed ID: 30185216
[TBL] [Abstract][Full Text] [Related]
5. The Development of Next-generation PBMC Humanized Mice for Preclinical Investigation of Cancer Immunotherapeutic Agents.
Morillon YM; Sabzevari A; Schlom J; Greiner JW
Anticancer Res; 2020 Oct; 40(10):5329-5341. PubMed ID: 32988851
[TBL] [Abstract][Full Text] [Related]
6. Antitumor Effect of Programmed Death-1 (PD-1) Blockade in Humanized the NOG-MHC Double Knockout Mouse.
Ashizawa T; Iizuka A; Nonomura C; Kondou R; Maeda C; Miyata H; Sugino T; Mitsuya K; Hayashi N; Nakasu Y; Maruyama K; Yamaguchi K; Katano I; Ito M; Akiyama Y
Clin Cancer Res; 2017 Jan; 23(1):149-158. PubMed ID: 27458246
[TBL] [Abstract][Full Text] [Related]
7. Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy.
Wang M; Yao LC; Cheng M; Cai D; Martinek J; Pan CX; Shi W; Ma AH; De Vere White RW; Airhart S; Liu ET; Banchereau J; Brehm MA; Greiner DL; Shultz LD; Palucka K; Keck JG
FASEB J; 2018 Mar; 32(3):1537-1549. PubMed ID: 29146734
[TBL] [Abstract][Full Text] [Related]
8. The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions.
Zhang T; Song X; Xu L; Ma J; Zhang Y; Gong W; Zhang Y; Zhou X; Wang Z; Wang Y; Shi Y; Bai H; Liu N; Yang X; Cui X; Cao Y; Liu Q; Song J; Li Y; Tang Z; Guo M; Wang L; Li K
Cancer Immunol Immunother; 2018 Jul; 67(7):1079-1090. PubMed ID: 29687231
[TBL] [Abstract][Full Text] [Related]
9. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous evaluation of treatment efficacy and toxicity for bispecific T-cell engager therapeutics in a humanized mouse model.
Yang J; Jiao J; Draheim KM; Yang G; Yang H; Yao LC; Shultz LD; Greiner DL; Rajagopal D; Vessillier S; Maier CC; Mohanan S; Cai D; Cheng M; Brehm MA; Keck JG
FASEB J; 2023 Jun; 37(6):e22995. PubMed ID: 37219526
[TBL] [Abstract][Full Text] [Related]
11. Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2R gamma(null) mice in vivo.
Ito A; Ishida T; Utsunomiya A; Sato F; Mori F; Yano H; Inagaki A; Suzuki S; Takino H; Ri M; Kusumoto S; Komatsu H; Iida S; Inagaki H; Ueda R
J Immunol; 2009 Oct; 183(7):4782-91. PubMed ID: 19748990
[TBL] [Abstract][Full Text] [Related]
12. Combination Therapy with Bispecific Antibodies and PD-1 Blockade Enhances the Antitumor Potency of T Cells.
Chang CH; Wang Y; Li R; Rossi DL; Liu D; Rossi EA; Cardillo TM; Goldenberg DM
Cancer Res; 2017 Oct; 77(19):5384-5394. PubMed ID: 28819027
[TBL] [Abstract][Full Text] [Related]
13. Modeling Tumor Immunology and Immunotherapy in Mice.
Buqué A; Galluzzi L
Trends Cancer; 2018 Sep; 4(9):599-601. PubMed ID: 30149876
[TBL] [Abstract][Full Text] [Related]
14. Construction of a Humanized PBMC-PDX Model to Study the Efficacy of a Bacterial Marker in Lung Cancer Immunotherapy.
Wu C; Wang X; Shang H; Wei H
Dis Markers; 2022; 2022():1479246. PubMed ID: 36072895
[TBL] [Abstract][Full Text] [Related]
15. An autologous humanized patient-derived-xenograft platform to evaluate immunotherapy in ovarian cancer.
Gitto SB; Kim H; Rafail S; Omran DK; Medvedev S; Kinose Y; Rodriguez-Garcia A; Flowers AJ; Xu H; Schwartz LE; Powell DJ; Simpkins F
Gynecol Oncol; 2020 Jan; 156(1):222-232. PubMed ID: 31818495
[TBL] [Abstract][Full Text] [Related]
16. Development of humanized mouse with patient-derived xenografts for cancer immunotherapy studies: A comprehensive review.
Jin KT; Du WL; Lan HR; Liu YY; Mao CS; Du JL; Mou XZ
Cancer Sci; 2021 Jul; 112(7):2592-2606. PubMed ID: 33938090
[TBL] [Abstract][Full Text] [Related]
17. Porcine cell microchimerism but lack of productive porcine endogenous retrovirus (PERV) infection in naive and humanized SCID-beige mice treated with porcine peripheral blood mononuclear cells.
Kuddus RH; Metes DM; Nalesnik MA; Logar AJ; Rao AS; Fung JJ
Transpl Immunol; 2004; 13(1):15-24. PubMed ID: 15203124
[TBL] [Abstract][Full Text] [Related]
18. Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2-/-IL2Rγnull Immunodeficient Mice.
Sanmamed MF; Rodriguez I; Schalper KA; Oñate C; Azpilikueta A; Rodriguez-Ruiz ME; Morales-Kastresana A; Labiano S; Pérez-Gracia JL; Martín-Algarra S; Alfaro C; Mazzolini G; Sarno F; Hidalgo M; Korman AJ; Jure-Kunkel M; Melero I
Cancer Res; 2015 Sep; 75(17):3466-78. PubMed ID: 26113085
[TBL] [Abstract][Full Text] [Related]
19. A mouse model for evaluation of efficacy and concomitant toxicity of anti-human CXCR4 therapeutics.
Costa MJ; Kudaravalli J; Liu WH; Stock J; Kong S; Liu SH
PLoS One; 2018; 13(3):e0194688. PubMed ID: 29554149
[TBL] [Abstract][Full Text] [Related]
20. NOD/SCID mice engrafted with human peripheral blood lymphocytes can be a model for investigating B cells responding to blood group A carbohydrate determinant.
Zhou W; Ohdan H; Tanaka Y; Hara H; Tokita D; Onoe T; Asahara T
Transpl Immunol; 2003; 12(1):9-18. PubMed ID: 14551028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
